Status:
COMPLETED
GLORIA-AF Registry Program - Second and Third Phases
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Stroke
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on importa...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age =\>18 years at enrollment
- Male or female patient (or legally acceptable representative) willing and able to provide written informed consent
- Patient newly diagnosed (\< 3 months prior to baseline visit) with non-valvular AF and at risk for stroke.
- Other inclusion criteria apply.
- Exclusion criteria:
- Presence of any mechanical heart valve, or valve disease that is expected to require valve replacement intervention;
- Patients who have received more than 60 days of vitamin K antagonist (VKA) treatment in their lifetime;
- AF with a generally reversible cause;
- Patients with a medical condition other than atrial fibrillation for which chronic use of an oral anticoagulant (for example, a VKA) is indicated Other exclusion criteria apply
Exclusion
Key Trial Info
Start Date :
November 7 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 10 2020
Estimated Enrollment :
37235 Patients enrolled
Trial Details
Trial ID
NCT01468701
Start Date
November 7 2011
End Date
January 10 2020
Last Update
March 29 2021
Active Locations (666)
Enter a location and click search to find clinical trials sorted by distance.
1
University South Alabama Medical Center
Mobile, Alabama, United States, 38817
2
Black Warrior Research
Northport, Alabama, United States, 35476
3
Scottsboro Quick Care Clinic
Scottsboro, Alabama, United States, 35768
4
Alaska Heart Institute
Anchorage, Alaska, United States, 99508